On this page
Ketoconazole
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Ketoconazole | 20 mg/mL | 197853 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Azole Antifungal [EPC] | EPC | All 44 members |
| Azoles [CS] | CS | All 44 members |
| Cytochrome P450 3A4 Inhibitors [MoA] | MoA | All 118 members |
| Cytochrome P450 3A5 Inhibitors [MoA] | MoA | 7 members — no class page |
| P-Glycoprotein Inhibitors [MoA] | MoA | All 105 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 076942-001 | KETOCONAZOLE | SHAMPOO | KETOCONAZOLE | Prescription | AB |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 24 | Labeling | Approved | February 18, 2020 | Standard |
| Supplement | 20 | Labeling | Approved | August 31, 2015 | Standard |
| Supplement | 19 | Labeling | Approved | January 3, 2013 | Standard |
| Supplement | 4 | Manufacturing (CMC) | Approved | October 17, 2007 | — |
| Original application | 1 | Approved | April 11, 2005 | — |
Review documents
- 0 · Original application · December 6, 2007
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250424). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Ketoconazole shampoo, 2%, is indicated for the treatment of tinea (pityriasis) versicolor caused by or presumed to be caused by Pityrosporum orbiculare (also known as Malassezia furfur or M. orbiculare ). Note: Tinea (pityriasis) versicolor may give rise to hyperpigmented or hypopigmented patches on the trunk which may extend to the neck, arms and upper thighs. Treatment of the infection may not immediately result in normalization of pigment to the affected sites. Normalization of pigment following successful therapy is variable and may take months, depending on individual skin type and incidental sun exposure. Although tinea versicolor is not contagious, it may recur because the organism that causes the disease is part of the normal skin flora.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Apply the shampoo to the damp skin of the affected area and a wide margin surrounding this area. Lather, leave in place for 5 minutes, and then rinse off with water. One application of the shampoo should be sufficient.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Ketoconazole shampoo, 2%, is contraindicated in persons who have known hypersensitivity to the active ingredient or excipients of this formulation.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Clinical Trials Experience In 11 double-blind trials in 264 patients using ketoconazole shampoo, 2%, for the treatment of dandruff or seborrheic dermatitis, an increase in normal hair loss and irritation occurred in less than 1% of patients. In three open-label safety trials in which 41 patients shampooed 4-10 times weekly for six months, the following adverse experiences each occurred once: abnormal hair texture, scalp pustules, mild dryness of the skin, and itching. As with other shampoos, oiliness and dryness of hair and scalp have been reported. In a double-blind, placebo-controlled trial in which patients with tinea versicolor were treated with either a single application of ketoconazole shampoo, 2%, (n=106), a daily application for three consecutive days (n=107), or placebo (n=105), drug-related adverse events occurred in 5 (5%), 7 (7%) and 4 (4%) of patients, respectively. The only events that occurred in more than one patient in any one of the three treatment groups were pruritus, application site reaction, and dry skin; none of these events occurred in more than 3% of the patients in any one of the three groups. Post-marketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency. The following adverse drug reactions have been identified during post-marketing experience with ketoconazole shampoo, 2%: there have been reports of hair discoloration and abnormal hair texture, itching, skin burning sensation, contact dermatitis, hypersensitivity, angioedema, alopecia, rash, urticaria, skin irritation, dry skin, and application site reactions.
Description
openFDA Drug LabelingDESCRIPTION Ketoconazole Shampoo, 2% is a red-orange liquid for topical application, containing the broad spectrum synthetic antifungal agent ketoconazole in a concentration of 2% in an aqueous suspension. It also contains: coconut fatty acid diethanolamide, disodium laureth sulfosuccinate, FD & C Red No. 40, hydrochloric acid, imidurea, laurdimonium hydroxypropyl hydrolyzed collagen, PEG-120 methyl glucose dioleate, purified water, sodium chloride, sodium hydroxide, and sodium lauryl ether sulfate. Ketoconazole is cis -1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1 H -imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy] phenyl]piperazine and has the following structural formula: Chemical Structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Ketoconazole shampoo, 2%, is intended for external use only. In the event of accidental ingestion, supportive and symptomatic measures should be employed. Induced emesis and gastric lavage should not be performed to avoid aspiration.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Ketoconazole Shampoo, 2%, is a red-orange liquid supplied in a 4-fluid ounce nonbreakable plastic bottle (NDC 68788-8868-1). Storage conditions: Store at 20oC to 25oC (68oF to 77oF) [see USP Controlled Room Temperature]. Protect from light. To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Distributed by: Cosette Pharmaceuticals, Inc. South Plainfield, NJ 07080 Rev. 07/2024 8-0592CP1 Relabeled By: Preferred Pharmaceuticals Inc.
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: KETOCONAZOLE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-3288-0 | 50090-3288 | A-S Medication Solutions | 118.28 mL in 1 BOTTLE, PLASTIC (50090-3288-0) | November 30, 2017 |
| 50090-7538-0 | 50090-7538 | A-S Medication Solutions | 120 mL in 1 BOTTLE, PLASTIC (50090-7538-0) | April 21, 2025 |
| 63629-8675-1 | 63629-8675 | Bryant Ranch Prepack | 120 mL in 1 BOTTLE (63629-8675-1) | February 9, 2022 |
| 71335-2839-1 | 71335-2839 | Bryant Ranch Prepack | 120 mL in 1 BOTTLE (71335-2839-1) | October 24, 2025 |
| 72162-1409-2 | 72162-1409 | Bryant Ranch Prepack | 120 mL in 1 BOTTLE (72162-1409-2) | June 20, 2024 |
| 0713-0592-04 | 0713-0592 | Cosette Pharmaceuticals, Inc. | 120 mL in 1 BOTTLE, PLASTIC (0713-0592-04) | February 7, 2025 |
| 72603-878-01 | 72603-878 | Northstar Rx LLC | 120 mL in 1 BOTTLE (72603-878-01) | December 1, 2025 |
| 68071-5294-4 | 68071-5294 | NuCare Pharmaceuticals, Inc. | 120 mL in 1 BOTTLE (68071-5294-4) | June 2, 2026 |
| 68071-3930-4 | 68071-3930 | NuCare Pharmaceuticals,Inc. | 120 mL in 1 BOTTLE (68071-3930-4) | December 8, 2025 |
| 45802-465-64 | 45802-465 | Padagis Israel Pharmaceuticals Ltd | 120 mL in 1 BOTTLE (45802-465-64) | January 19, 2010 |
| 68788-8257-1 | 68788-8257 | Preferred Pharmaceuticals Inc. | 120 mL in 1 BOTTLE, PLASTIC (68788-8257-1) | September 16, 2022 |
| 68788-8868-1 | 68788-8868 | Preferred Pharmaceuticals Inc. | 120 mL in 1 BOTTLE, PLASTIC (68788-8868-1) | April 24, 2025 |
| 71205-105-72 | 71205-105 | Proficient Rx LP | 120 mL in 1 BOTTLE, PLASTIC (71205-105-72) | September 4, 2018 |
| 71713-097-04 | 71713-097 | THIRTY MADISON INC | 120 mL in 1 BOTTLE, PLASTIC (71713-097-04) | April 11, 2005 |
| 63646-010-04 | 63646-010 | TOLMAR Inc. | 120 mL in 1 BOTTLE, PLASTIC (63646-010-04) | April 11, 2005 |
| 50090-3288 | 50090-3288 | A-S Medication Solutions | — | April 11, 2005 |
| 50090-7538 | 50090-7538 | A-S Medication Solutions | — | February 7, 2025 |
| 63629-8675 | 63629-8675 | Bryant Ranch Prepack | — | January 19, 2010 |
| 71335-2839 | 71335-2839 | Bryant Ranch Prepack | — | January 19, 2010 |
| 72162-1409 | 72162-1409 | Bryant Ranch Prepack | — | January 19, 2010 |
| 0713-0592 | 0713-0592 | Cosette Pharmaceuticals, Inc. | — | February 7, 2025 |
| 72603-878 | 72603-878 | Northstar Rx LLC | — | December 1, 2025 |
| 68071-5294 | 68071-5294 | NuCare Pharmaceuticals, Inc. | — | December 1, 2025 |
| 68071-3930 | 68071-3930 | NuCare Pharmaceuticals,Inc. | — | January 19, 2010 |
| 45802-465 | 45802-465 | Padagis Israel Pharmaceuticals Ltd | — | January 19, 2010 |
| 68788-8257 | 68788-8257 | Preferred Pharmaceuticals Inc. | — | September 16, 2022 |
| 68788-8868 | 68788-8868 | Preferred Pharmaceuticals Inc. | — | April 24, 2025 |
| 71205-105 | 71205-105 | Proficient Rx LP | — | October 1, 2016 |
| 71713-097 | 71713-097 | THIRTY MADISON INC | — | April 11, 2005 |
| 63646-010 | 63646-010 | TOLMAR Inc. | — | April 11, 2005 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.